CliffBio
biologic

Elfabrio

pegunigalsidase alfa-iwxj

Loss of exclusivityMay 2036projected — 12-year biologic exclusivity estimate
CompanyChiesi Farmaceutici S.p.A. →See this company's full patent-cliff portfolio

Drug detail

Brand nameElfabrio
Active ingredientpegunigalsidase alfa-iwxj
Strength5MG/2.5ML
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalMay 2024
Marketing statusRx

More from Chiesi Farmaceutici S.p.A.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.